• "A tumor deconstruction platform for the analysis of intra-tumor heterogeneity"
• "Identification, quantification, monitoring and analysis of intra-tumor heterogeneity"
• Indian application No. 173/MUM/2014 (filed on 20 January 2014)
• PCT Application Number: PCT/IB2015/050358 (filed on 17 January 2015)

Abstract

The present invention provides a method for concurrent resolution of the cancer stem cell (CSC) derived hierarchy, genetic instability, differentially cycling cells and host cells recruited for performing tumor growth supporting functions; and quantification, monitoring and analysis of these populations. The first level of analysis can be carried out using either CSC- and progenitor-specific markers or a marker-free approach based on label-chase to resolve the tumor regenerative hierarchy. The next level involves combinatorial quantification of differential DNA-RNA contents to identify recruited host and tumor cell variants resulted from genetic instability and differential cycling within the tumor.

“A Monoclonal Antibody Targeting the Tumor Regenerative Hierarchy”

Indian application No. 2980/MUM/2014 (filed on 18 September 2014).

Abstract

The present invention presents a novel monoclonal antibody and methods of its use. The said antibody, termed as mAb150 displays cytoreductive effects and targets Annexin II (Anxa2) expressing quiescent cancer stem cells, proliferative progenitors and to a lesser extent, differentiated tumor cells. Thereby, mAb150 exhibits a novel cell specificity that can destroy the Anxa2-associated tumor regenerative hierarchy. We also demonstrate a mechanism to improve the efficacy of mAb150 either by enhancing Anxa2 expression of tumors and / or complementation with other drugs to target non-Anxa2 expressing cells. The present invention is thus crucial in the design of optimal drug combinations towards achieve total remission by eliminating drug resistant cell populations and minimal residual disease.

‘Method of Preparing Dialysed Extract of Fenugreek Seeds’

US patent No.: US 8,865,237 B2 (granted)

International Filing Date: 27.06.2006
Priority Date: 01.06.2006

WIPO Publication. No.:WO/2007/138609

Introduction

Fenugreek (Trigonella foenum graecum), an annual medicinal plant of the Fabaceae family, is well documented for its pharmacological properties. The aqueous extract and the powder of the seeds of fenugreek have been shown to be safe for long-term use and non-toxicity in animal models of metabolic diseases as well as in humans. In animal and several small human trials, fenugreek seeds have been found to lower fasting serum glucose and lipid levels. However, considering the pungent odor and bitter taste of fenugreek seeds, requirement of high dose has been a problem to be solved. Here, we have come up with novel clinically administrable preparations of fenugreek seeds that can correct alterations associated with carbohydrate and lipid metabolism (Diabetes/dyslipidemia/obesity).

This invention is related to method of preparing dialyzed aqueous extract of fenugreek seeds that is capable of activating insulin signaling pathway/GLUT4 mediated glucose uptake. This novel extract made by this process can be scaled up for potential application in the management of diabetes.

Abstract: A method of preparing dialysed aqueous extract of fenugreek seeds comprising washing the fenugreek seeds is distilled water, sterilizing the said seeds, subjecting the sterilized seeds to the step of grinding to form powder, suspending the said powder in phosphate buffered saline (PBS), subjecting the said suspension to the step of filtration to obtain the filtrate, treating the filtrate with activated charcoal to obtain clear supernatant, subjecting the supernatant to the step of lyophilization and the powder thus obtained was dissolved in phosphate buffered saline (PBS), dialyzed fenugreek seed extract (FSE) which can be aliquoted and stored.

‘Protein Based Product from Fenugreek Seeds That Regulates Dyslipidemia and Obesity, and a Process for the Preparation Thereof’

International Application No.: PCT/IN2008/000877
International Filing Date: 30.09.2008
Priority Date:  25.06. 2008
Indian Patent application No.:1621/DEL/2008
WIPO Publication number: WO/2009/157013
European Patent Application No. 08 874 801

Introduction:

Fenugreek (Trigonella foenum graecum), an annual medicinal plant of the Fabaceae family, is well documented for its pharmacological properties. The aqueous extract and the powder of the seeds of fenugreek have been shown to be safe for long-term use and non-toxicity in animal models of metabolic diseases as well as in humans. In animal and several small human trials, fenugreek seeds have been found to lower fasting serum glucose and lipid levels. However, considering the pungent odor and bitter taste of fenugreek seeds, requirement of high dose has been a problem to be solved. Here, we have come up with novel clinically administrable preparations of fenugreek seeds that can correct alterations associated with carbohydrate and lipid metabolism (Diabetes/dyslipidemia/obesity).

This invention is related to development of a process for preparation of a protein rich product from Fenugreek Seeds Extract (TEFS) which is capable of decreasing accumulation of fat and enhances LDL uptake, and has potential application in obesity and dyslipidemia.

Abstract:

This invention relates to a protein based product from fenugreek seeds (TEFS), comprising: Grinding of dried fenugreek seeds suspending ground fine powder of the fenugreek seeds in PBS, pH 7.4 containing 0.1 mM PMSF and protease inhibitor cocktail under chilled conditions; filtering the extract through three layered cheese cloth, centrifuging; treating clear supernatant with activated charcoal powder; extracting or precipitating protein; removing the precipitate by centrifugation, re-dissolving in PBS and dialyzing against PBS; heat treating the dialyzed protein rich extract; removing the precipitated protein by centrifugation and retrieving supernatant as final product. Said final product has a protein concentration of 0.1-15 mg/ml, preferably 1-1.5 mg/ml. Said product is useful in the management of dyslipidemia and obesity.

‘Tumor suppressor activating polypeptides and uses thereof’

US Patent No.: US 8,420,100 B2 (granted)

Indian patent file number: IPR/4.19.20/06083/2006. PCT: 06083

Abstract: Chimeric tumor suppressor activating peptides derived from matrix attachment region binding protein (MARBP) SMARI unique in their sequence comprising a arginine rich motif flanked by serine residues wherein from the stretch of four consecutive serine residues the first serine residue gets phosphorylated by the protein kinase C family of serine threonine kinases being indispensable for its functionality, the phosphorylation being directly correlated to the phosphorylation of p53 at serine 15 residue thereby stabilizing it, wherein the peptide activates p53 by modifying it post translationally which allow phosphorylation and translocation of p53 to the nucleus.

'Creation of an Artificial Bone Marrow micro Environment (ABME) and uses thereof'

(patent jointly with TIFR, Mumbai)

Granted: Australia : 2005328537; New Zealand : 560813; Korea : 2007-7020266; ARIPO : AP/P/2007/00416; Japan : 2007-557602; Singapore : Patent no: 134945;

Indian Patent No: 247460

Pending:Europe : 05759972.2; U.S.A.: 11/817,173; Canada : 2,598,936; Brazil: PI 0518543-2; Israel: 185516; China: 200580048925.2

Abstract: Artificial Bone marrow Environments (ABME) is a platform technology that can be developed into products useful in therapeutic as well as non-therapeutic applications. Therapeutic applications: ABME can be used to accelerate engraftment of stem cell in transplantation, stimulation of endogenous stem cell pool in BM failure patients, to accelerate wound healing and to increase the potency of mesenchymal stem cells in various non-hematological disorders. Non-therapeutic applications: ABME can be used for drug screening, drug toxicity, identification of niche defects, development of novel stem cell assays, quality control parameter to assess stem cell and niche functionality, comparison between various stem cell sources, etc.

‘A pharmaceutical composition having virucidal and spermicidal activity’

US 08729034 B2 (filed by CSIR on behalf of IICB, Kolkata)

Abstract: Acaciaside-B (Ac-B) has emerged as a prospective candidate molecule for prevention of HIV infection along with potential for use as/in vaginal contraceptive/formulation. It possesses anti-HIV property at a tolerably low concentration, is non-mutagenic and does not harm the niche of Lactobacilli. Thus Ac-B appears to be a superior ingredient for formulations of a chemical barrier against HIV-1 infection wherein its spermicidal property is superfluous.

‘Anti-tumor activity of AECHL-1, novel triterpenoid isolated from Ailanthus excelsa in vitro and in vivo’

US Patent no: US8519163 B2

Abstract: A novel chemical moiety triterpenoid AECHL-1 isolated from root bark of Ailanthus excelsa having anti-cancer properties exhibiting remarkable activity in treatment of various forms of tumors with specificity, wherein it blocks the growth of four tumor cell lines with distinct origins and of different p53 status (B16F10 mouse melanoma, PC3 human prostate cancer, MCF-7 and MDA-MB-231 human breast cancer).